270 related articles for article (PubMed ID: 37600670)
1. HER2-Low Breast Cancer: Current Landscape and Future Prospects.
Shirman Y; Lubovsky S; Shai A
Breast Cancer (Dove Med Press); 2023; 15():605-616. PubMed ID: 37600670
[TBL] [Abstract][Full Text] [Related]
2. Current Biological, Pathological and Clinical Landscape of HER2-Low Breast Cancer.
Zhang H; Peng Y
Cancers (Basel); 2022 Dec; 15(1):. PubMed ID: 36612123
[TBL] [Abstract][Full Text] [Related]
3. HER2-Low Breast Cancer-Diagnostic Challenges and Opportunities for Insights from Ongoing Studies: A Podcast.
Bardia A; Viale G
Target Oncol; 2023 May; 18(3):313-319. PubMed ID: 37133651
[TBL] [Abstract][Full Text] [Related]
4. The evolving therapeutic landscape of trastuzumab-drug conjugates: Future perspectives beyond HER2-positive breast cancer.
von Arx C; De Placido P; Caltavituro A; Di Rienzo R; Buonaiuto R; De Laurentiis M; Arpino G; Puglisi F; Giuliano M; Del Mastro L
Cancer Treat Rev; 2023 Feb; 113():102500. PubMed ID: 36587473
[TBL] [Abstract][Full Text] [Related]
5. Open questions, current challenges, and future perspectives in targeting human epidermal growth factor receptor 2-low breast cancer.
Curigliano G; Dent R; Earle H; Modi S; Tarantino P; Viale G; Tolaney SM
ESMO Open; 2024 Apr; 9(4):102989. PubMed ID: 38613914
[TBL] [Abstract][Full Text] [Related]
6. HER2-Low Breast Cancer: a New Subtype?
Corti C; Giugliano F; Nicolò E; Tarantino P; Criscitiello C; Curigliano G
Curr Treat Options Oncol; 2023 May; 24(5):468-478. PubMed ID: 36971965
[TBL] [Abstract][Full Text] [Related]
7. The HER2-low revolution in breast oncology: steps forward and emerging challenges.
Nicolò E; Boscolo Bielo L; Curigliano G; Tarantino P
Ther Adv Med Oncol; 2023; 15():17588359231152842. PubMed ID: 36844387
[TBL] [Abstract][Full Text] [Related]
8. Impact of Human Epidermal Growth Factor Receptor 2 (HER2) Low Status in Response to Neoadjuvant Chemotherapy in Early Breast Cancer.
Alves FR; Gil L; Vasconcelos de Matos L; Baleiras A; Vasques C; Neves MT; Ferreira A; Fontes-Sousa M; Miranda H; Martins A
Cureus; 2022 Feb; 14(2):e22330. PubMed ID: 35371692
[TBL] [Abstract][Full Text] [Related]
9. Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions.
Ferraro E; Drago JZ; Modi S
Breast Cancer Res; 2021 Aug; 23(1):84. PubMed ID: 34380530
[TBL] [Abstract][Full Text] [Related]
10. Trastuzumab deruxtecan in HER2-positive metastatic breast cancer and beyond.
Perez J; Garrigós L; Gion M; Jänne PA; Shitara K; Siena S; Cortés J
Expert Opin Biol Ther; 2021 Jul; 21(7):811-824. PubMed ID: 33759669
[TBL] [Abstract][Full Text] [Related]
11. Can Patients with HER2-Low Breast Cancer Benefit from Anti-HER2 Therapies? A Review.
Wang J; Liao D; Zhang X; Miao C; Chen K
Breast Cancer (Dove Med Press); 2023; 15():281-294. PubMed ID: 37113514
[TBL] [Abstract][Full Text] [Related]
12. Effects of Ado-Trastuzumab Emtansine and Fam-Trastuzumab Deruxtecan on Metastatic Breast Cancer Harboring HER2 Amplification and the L755S Mutation.
Mukohara T; Hosono A; Mimaki S; Nakayama A; Kusuhara S; Funasaka C; Nakao T; Fukasawa Y; Kondoh C; Harano K; Naito Y; Matsubara N; Tsuchihara K; Kuwata T
Oncologist; 2021 Aug; 26(8):635-639. PubMed ID: 33559918
[TBL] [Abstract][Full Text] [Related]
13. Low and Ultra-Low HER2 in Human Breast Cancer: An Effort to Define New Neoplastic Subtypes.
Franchina M; Pizzimenti C; Fiorentino V; Martini M; Ricciardi GRR; Silvestris N; Ieni A; Tuccari G
Int J Mol Sci; 2023 Aug; 24(16):. PubMed ID: 37628975
[TBL] [Abstract][Full Text] [Related]
14. The Exciting New Field of HER2-Low Breast Cancer Treatment.
Eiger D; Agostinetto E; Saúde-Conde R; de Azambuja E
Cancers (Basel); 2021 Mar; 13(5):. PubMed ID: 33804398
[TBL] [Abstract][Full Text] [Related]
15. Systemic Therapy for HER2-Positive Metastatic Breast Cancer: Current and Future Trends.
Vega Cano KS; Marmolejo Castañeda DH; Escrivá-de-Romaní S; Saura C
Cancers (Basel); 2022 Dec; 15(1):. PubMed ID: 36612047
[TBL] [Abstract][Full Text] [Related]
16. The efficacy of trastuzumab-deruxtecan for the treatment of patients with advanced HER2-low breast cancer.
Schlam I; Tolaney SM; Tarantino P
Expert Rev Anticancer Ther; 2023 Sep; ():1-8. PubMed ID: 36691884
[TBL] [Abstract][Full Text] [Related]
17. Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low-Expressing Advanced Breast Cancer: Results From a Phase Ib Study.
Modi S; Park H; Murthy RK; Iwata H; Tamura K; Tsurutani J; Moreno-Aspitia A; Doi T; Sagara Y; Redfern C; Krop IE; Lee C; Fujisaki Y; Sugihara M; Zhang L; Shahidi J; Takahashi S
J Clin Oncol; 2020 Jun; 38(17):1887-1896. PubMed ID: 32058843
[TBL] [Abstract][Full Text] [Related]
18. How I treat HER2-low advanced breast cancer.
Schlam I; Tolaney SM; Tarantino P
Breast; 2023 Feb; 67():116-123. PubMed ID: 36669993
[TBL] [Abstract][Full Text] [Related]
19. HER2-low breast cancers: Current insights and future directions.
Zhang H; Karakas C; Tyburski H; Turner BM; Peng Y; Wang X; Katerji H; Schiffhauer L; Hicks DG
Semin Diagn Pathol; 2022 Sep; 39(5):305-312. PubMed ID: 35872032
[TBL] [Abstract][Full Text] [Related]
20. Spotlight on Trastuzumab Deruxtecan (DS-8201,T-DXd) for
Azar I; Alkassis S; Fukui J; Alsawah F; Fedak K; Al Hallak MN; Sukari A; Nagasaka M
Lung Cancer (Auckl); 2021; 12():103-114. PubMed ID: 34675733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
